The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study

Background Large Phase III trials across Asia and Latin America have recently demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 mo following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns...

Full description

Bibliographic Details
Main Authors:	Flasche, S, Jit, M, Rodríguez-Barraquer, I, Coudeville, L, Recker, M, Koelle, K, Milne, G, Hladish, TJ, Perkins, TA, Cummings, DAT, Dorigatti, I, Laydon, DJ, España, G, Kelso, J, Longini, I, Lourenco, J, Pearson, CAB, Reiner, RC, Mier-Y-Terán-Romero, L, Vannice, K, Ferguson, N
Format:	Journal article
Language:	English
Published:	Public Library of Science 2016

The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study

Similar Items